Table 4.
Comparison of genotype frequencies between RA patients with or without anti-TNF therapy, as marker of disease severity
| SNP | Genotype frequency | p trenda | SNP | Genotype frequency | p trenda | ||
|---|---|---|---|---|---|---|---|
| No anti-TNF | Anti-TNF | No anti-TNF | Anti-TNF | ||||
| 250 n (%) | 120 n (%) | 250 n (%) | 120 n (%) | ||||
| IL6-174 | NOS2a 608 | ||||||
| C/C | 33 (15.1) | 22 (19.8) | 0.06 | G/G | 175 (70.9) | 75 (64.1) | 0.18 |
| C/G | 83 (37.9) | 49 (44.1) | G/A | 65 (26.3) | 37 (31.6) | ||
| G/G | 103 (47.0) | 40 (36.0) | A/A | 7 (2.8) | 5 (4.3) | ||
| IL8 781 | PARP 762 | ||||||
| C/C | 97 (38.8) | 43 (35.8) | 0.92 | T/T | 180 (73.2) | 75 (64.1) | 0.37 |
| C/T | 108 (43.2) | 58 (48.3) | T/C | 55 (22.4) | 41 (35.0) | ||
| T/T | 45 (18.0) | 19 (15.8) | C/C | 11 (4.5) | 1 (0.9) | ||
| PAI1 4/5G | IL4-524 | ||||||
| 5G/5G | 67 (27.6) | 33 (28.4) | 0.97 | C/C | 177 (71.7) | 87 (73.1) | 0.62 |
| 5G/4G | 116 (47.7) | 53 (45.7) | C/T | 60 (24.3) | 29 (24.4) | ||
| 4G/4G | 60 (24.7) | 30 (25.9) | T/T | 10 (4) | 3 (2.5) | ||
| TNFA-863 | C1INH 480 | ||||||
| C/C | 155 (62.8) | 78 (67.2) | 0.42 | G/G | 143 (58.8) | 65 (57.5) | 0.62 |
| C/A | 87 (35.2) | 36 (31.0) | G/A | 82 (33.7) | 45 (39.8) | ||
| A/A | 5 (2.0) | 2 (1.7) | A/A | 18 (7.4) | 3 (2.7) | ||
| TNFA-857 | II10-1082 | ||||||
| C/C | 212 (87.2) | 96 (84.2) | 0.52 | G/G | 61 (25.7) | 25 (21.9) | 0.55 |
| C/T | 30 (12.3) | 18 (15.8) | G/A | 112 (47.3) | 57 (50.0) | ||
| T/T | 1 (0.4) | A/A | 64 (27.0) | 32 (28.1) | |||
| TNFA-376 | IL10-819 | ||||||
| G/G | 248 (99.2) | 118 (98.3) | 0.45 | C/C | 153 (63.2) | 75 (63.6) | 0.72 |
| G/A | 2 (0.8) | 2 (1.7) | C/T | 65 (26.9) | 34 (28.8) | ||
| A/A | T/T | 24 (9.9) | 9 (7.6) | ||||
| TNFA-308 | TLR4 299 | ||||||
| G/G | 156 (62.4) | 89 (74.2) | 0.13 | A/A | 206 (83.7) | 104 (88.1) | 0.24 |
| G/A | 91 (36.4) | 26 (21.7) | A/G | 39 (15.9) | 14 (11.9) | ||
| A/A | 3 (1.2) | 5 (4.2) | G/G | 1 (0.4) | |||
| TNFA-238 | TLR4 399 | ||||||
| G/G | 243 (97.2) | 111 (92.5) | 0.04 | C/C | 206 (83.7) | 103 (87.3) | 0.34 |
| G/A | 7 (2.8) | 9 (7.5) | C/T | 39 (15.9) | 15 (12.7) | ||
| A/A | T/T | 1 (0.4) | |||||
| IL1B-31 | |||||||
| C/C | 30 (12.0) | 17 (14.3) | 0.68 | ||||
| C/T | 116 (46.4) | 46 (38.6) | |||||
| T/T | 104 (41.6) | 56 (47.1) | |||||
Only patients for whom data regarding medication were complete (n = 370) were included.
a. Cochrane-Armitage trend test for additive effects. p value represents analysis not corrected for multiple testing. When Bonferroni correction is applied none of the polymorphism tested remain significant.